Abstract:Background Ischemia is a well-established contributor to vascular dementia. Indeed, the most common pathology in people with dementia is mixed, and over half of patients diagnosed with AD have demonstrable vascular pathologies. Ischemia induces an immune response which triggers secondary neurodegeneration remote to the initial lesion, and consequent cognitive decline. Ischemia-triggered vascular dementia is dependent on B-lymphocytes driving chronic neuroinflammation in adult mice. However, vascular dementia is most common in the aged, and there are key differences in inflammatory responses with age. Vascular cell adhesion molecule 1 (VCAM1) is an endothelial protein that facilitates vascular-immune crosstalk via interaction with very late antigen-4 (VLA-4). Soluble VCAM1 is elevated in stroke, vascular dementia, and normal aging in both people and mice. In aging mice, anti-VCAM1 ameliorates age-induced neuroinflammation and cognitive impairment. Although the mechanism is unclear, this is likely mediated via changes in endothelial cell activation and secretion of pro-inflammatory mediators. Therefore, we hypothesized that acute anti-VCAM1 treatment would reduce microgliosis and astrogliosis, while delayed treatment would reduce B and T lymphocyte infiltration in a mouse model of ischemia-triggered vascular dementia. Method Adult (3-month-old) or aged (10-month-old) C57BL/6J mice (n=10-15/group) underwent permanent distal middle cerebral artery occlusion. Mice were dosed with anti-VCAM1 antibody either 4 hours or 4 days post-ischemia, and then sacrificed at 72 hours, 3 weeks or 6 weeks post-ischemia. Microgliosis and astrogliosis were quantified as percent area immunostained in the lesion border by CD68 and GFAP, respectively. B and T cell infiltration were quantified as percent lesion immunostained by B220, and CD3+ cells in the ischemic lesion, respectively. Result Acute treatment reduced microgliosis 30% ( p=0.0476 ) and astrogliosis 39% (p<0.03). In adults, delayed anti-VCAM1 significantly reduced B and T cell infiltration approximately 25% ( p=0.0015 ) and 50% ( p=0.0192 ), respectively. Similarly, in aged mice, delayed anti-VCAM1 significantly reduced B and T cell infiltration approximately 50% ( p=0.0037 ) and 30% ( p=0.0036 ), respectively. In contrast, early anti-VCAM1 had little or no effect on B or T cell infiltration. Conclusion Together, these findings establish VCAM1 as a possible therapeutic target to ameliorate ischemia-induced neuroinflammation and consequent cognitive decline in a mouse model of vascular dementia.

The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia

Inflammation, apoptosis and autophagy as critical players in vascular dementia

Cerebral Microvascular Dysfunction and Neurodegeneration in Dementia

Neuroinflammatory Responses Occur in Brain Lesions During Alzheimer's Disease: Postmortem Case Report

Neuroinflammation in Vascular Cognitive Impairment and Dementia: Current Evidence, Advances, and Prospects

Inflammation and Rho-Associated Protein Kinase-Induced Brain Changes in Vascular Dementia

Pathologic sequelae of vascular cognitive impairment and dementia sheds light on potential targets for intervention

Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease

Neurovascular unit, neuroinflammation and neurodegeneration markers in brain disorders

Vascular Dementia and Crosstalk Between the Complement and Coagulation Systems

Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer's disease

Neurobiochemical Mechanisms of Vascular Dementia

Emerging Biomarkers in Vascular Cognitive Impairment and Dementia: From Pathophysiological Pathways to Clinical Application

Targeting VCAM1 to reduce neuroinflammation in ischemia‐triggered vascular dementia

Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia

Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia

Unraveling Pathophysiological Link Between Mitophagy Pathway and Vascular Dementia

Loss of Direct Vascular Contact to Astrocytes in the Hippocampus as an Initial Event in Alzheimer's Disease. Evidence from Patients, In Vivo and In Vitro Experimental Models

Exploratory Transcriptomic Profiling Reveals the Role of Gut Microbiota in Vascular Dementia

Axon-glial Disruption: the Link Between Vascular Disease and Alzheimer's Disease?

Parallel neuroinflammatory pathways to cerebrovascular injury and amyloid-beta in Alzheimer's disease